52-Week Efficacy and Safety of Telbivudine with Conditional Tenofovir Intensification at Week 24 in HBeAg-Positive Chronic Hepatitis B

Files in this item

This item appears in the following Collection(s)

Search DSpace



Browse

My Account

Statistics